Immunotherapy plus chemo shows promise for esophageal cancer in early trial
NCT ID NCT06869213
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy before and after surgery can help patients with locally advanced esophageal cancer. About 30 participants will receive three cycles of the combination before surgery, then continue adebrelimab alone after surgery to prevent recurrence. The main goals are to see how many patients have no cancer cells left after treatment and to monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (a PD-L1 inhibitor) combined with nab-paclitaxel and cisplatin chemotherapy
What this could lead to
If successful, this could lead to a new treatment option that improves outcomes for patients with resectable esophageal cancer by using immunotherapy alongside standard chemotherapy before and after surgery.
What could go wrong
This is a small, early-phase (phase 2) study with only 30 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet proven to be better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••